Compare TEVA & EXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | EXPE |
|---|---|---|
| Founded | 1901 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 30.5B |
| IPO Year | N/A | 1999 |
| Metric | TEVA | EXPE |
|---|---|---|
| Price | $28.38 | $263.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 28 |
| Target Price | $27.00 | ★ $249.12 |
| AVG Volume (30 Days) | ★ 11.4M | 2.7M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 0.61% |
| EPS Growth | N/A | ★ 35.97 |
| EPS | 0.62 | ★ 10.37 |
| Revenue | ★ $16,776,000,000.00 | $14,370,000,000.00 |
| Revenue This Year | $4.74 | $8.74 |
| Revenue Next Year | $0.48 | $7.19 |
| P/E Ratio | $46.12 | ★ $25.40 |
| Revenue Growth | 0.02 | ★ 7.29 |
| 52 Week Low | $12.47 | $130.01 |
| 52 Week High | $28.68 | $279.61 |
| Indicator | TEVA | EXPE |
|---|---|---|
| Relative Strength Index (RSI) | 80.93 | 61.48 |
| Support Level | $24.01 | $257.63 |
| Resistance Level | $26.96 | $266.00 |
| Average True Range (ATR) | 0.68 | 8.11 |
| MACD | 0.19 | 0.09 |
| Stochastic Oscillator | 94.65 | 91.25 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.